Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MannKind: Q2 Earnings Snapshot AP - Wed Aug 5, 3:44PM CDT

MannKind: Q2 Earnings Snapshot

MNKD : 3.89 (-5.12%)
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Wed Aug 5, 3:01PM CDT

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment...

MNKD : 3.89 (-5.12%)
MannKind's Pipeline Enthusiasm Meets a DCF Model That Suggests Fifteen Dollars Lower Barchart - Tue Aug 4, 4:22PM CDT

Barchart Research What to Expect from MNKD Earnings MNKD Generated August 4, 2026 Current Price $3.96 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.97% MannKind's Pipeline Enthusiasm...

MNKD : 3.89 (-5.12%)
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF GlobeNewswire - Wed Jul 29, 5:30AM CDT

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough ~450 total inhalations administered...

MNKD : 3.89 (-5.12%)
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 GlobeNewswire - Tue Jul 28, 3:01PM CDT

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that the Company will report second quarter 2026 financial results...

MNKD : 3.89 (-5.12%)
MannKind Announces $50 Million Private Placement GlobeNewswire - Fri Jul 24, 5:35AM CDT

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 3.89 (-5.12%)
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease GlobeNewswire - Fri Jul 24, 5:30AM CDT

Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital setting Delivers IV-equivalent diuretic...

MNKD : 3.89 (-5.12%)
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D GlobeNewswire - Tue Jun 23, 8:00AM CDT

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE...

MNKD : 3.89 (-5.12%)
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems GlobeNewswire - Fri Jun 5, 6:35PM CDT

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize...

MNKD : 3.89 (-5.12%)
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF GlobeNewswire - Wed Jun 3, 5:05AM CDT

Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical...

MNKD : 3.89 (-5.12%)

Barchart Exclusives

The Data Center Boom Is Powering Utility Earnings. Here Is My Favorite Way to Play the Trend. Barchart - Thu Aug 6, 6:30PM CDT
Utility companies are increasingly benefiting from the AI data center boom, and here is my favorite way to gain exposure to this investment theme. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.